On December 3, 2025, stockholders of Galectin Therapeutics Inc. elected directors and approved executive compensation practices, deciding on advisory votes every three years; 25.3 million votes supported compensation. The independent auditor for 2025 was also ratified, with over 45.4 million votes in favor.